Precede Biosciences

📍 Boston, MA, United States🗓 Founded 2021👥 55 employees💰 Last funded Dec 2025
Biotechnology Research🌐 precede.bio
Website LinkedIn
Weve experienced the significant gaps in our collective ability, as a medical and research community, to access and understand disease-defining biology when it matters most. To address this, Precede Bio developed a simple blood test to uncover actionable disease-defining transcriptional biology.  Our unique genome-wide platform profiles circulating chromatin and the DNA methylome to deliver resolution into the dynamic activity of individual genes and pathways in diseased tissues from just 1mL of plasma.  By partnering with developers of new medicines and advancing our own diagnostic tests, we’re working towards a world where new medicine development efforts succeed more frequently, and where anyone can receive a minimally invasive diagnosis and treatment that’s precise to the biology of their disease.
2
Total investors
1
Early stage
1
Mid stage
0
Late stage
2021
Founded

Investors

2 investors
All
Early stage
Mid stage
Late stage
Investor geography1 country
United States
2
Frequently asked questions
Who invested in Precede Biosciences?
Precede Biosciences has 2 investors on record on gritt.io, including 1 early-stage backers, 1 mid-stage.
When did Precede Biosciences last raise funding?
The most recent investment in Precede Biosciences recorded on gritt.io was in December 2025.
When was Precede Biosciences founded?
Precede Biosciences was founded in 2021.
What industry is Precede Biosciences in?
Precede Biosciences operates in Biotechnology Research. Find similar Biotechnology Research investors on gritt.io.
Where is Precede Biosciences based?
Precede Biosciences is headquartered in Boston, MA, United States.